Previous 10 | Next 10 |
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV Halozyme's drug delivery technology provides the opportunity to administer large volume subcuta...
Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire SAN DIEGO , June 1, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) t...
Halozyme to Present at Upcoming Investor Conferences PR Newswire SAN DIEGO , May 28, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it will participate at the following investor conferences: The Goldman Sachs 42nd Ann...
Halozyme is currently in the stalwart phase with approximately less than 50% more upsides. The company shifted focus to employing a low-risk business model. They're out-licensing their Enhanze technology to other large pharmas. With an increasing number of blockbusters being refor...
Janssen Pharmaceutica, a unit of Johnson & Johnson ([[JNJ]] +0.6%) has received two positive opinions from the European Medicines Agency ((EMA)) to broaden the current marketing authorization for DARZALEX (daratumumab) subcutaneous formulation ((SC)).One recommendation is for it...
Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE® - For Use of Subcutaneous Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (D-VCd) in Newly Diagnosed Ad...
Novavax cut to neutral at JP Morgan; manufacturing issues citedNovavax (NVAX) topped Street estimates with its Q1 2021 financials, but a delayed timeline outlined for its COVID-19 vaccine candidate hurt the stock yesterday leading to a ~14.4% slump.Today, J.P. Morgan has downgraded ...
Image source: The Motley Fool. Halozyme Therapeutics Inc (NASDAQ: HALO) Q1 2021 Earnings Call May 10, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Halozyme Therapeutics Inc (HALO) Q1 2021 Earnings Call Transcript...
Halozyme Reports First Quarter 2021 Results - First Quarter Revenue of $89.0 million, Up from $25.4 million in First Quarter of 2020 - - Record Quarterly Royalties in the First Quarter of $36.9 million Representing 119% Growth over First Quarter 2020 - - Reiterate 2021 R...
[[ACM]], [[AEE]], [[AFRM]], [[BHF]], [[BRKS]], [[CNNE]], [[CPSI]], [[CSTL]], [[DDD]], [[EGHT]], [[ELY]], [[EVBG]], [[FGEN]], [[FOE]], [[G]], [[HALO]], [[HHC]], [[HLIO]], [[IFF]], [[INO]], [[IPAR]], [[JCOM]], [[MBI]], [[MESA]], [[MGNI]], [[MODN]], [[MRVI]], [[NCMI]], [[NHI]], [[NLOK]], [[NLS]]...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...